f | { | f | { |
| "author": "", | | "author": "", |
| "author_email": "", | | "author_email": "", |
| "creator_user_id": "0124c449-4279-4839-a7e2-f7ee873dbc7c", | | "creator_user_id": "0124c449-4279-4839-a7e2-f7ee873dbc7c", |
| "groups": [ | | "groups": [ |
| { | | { |
| "description": "Group for publications", | | "description": "Group for publications", |
| "display_name": "Publication", | | "display_name": "Publication", |
| "id": "816c3c41-f871-427d-9e26-fb21e6b3c578", | | "id": "816c3c41-f871-427d-9e26-fb21e6b3c578", |
| "image_display_url": | | "image_display_url": |
| mw/uploads/group/2022-03-17-123757.433896243660articlesquareicon.png", | | mw/uploads/group/2022-03-17-123757.433896243660articlesquareicon.png", |
| "name": "publication", | | "name": "publication", |
| "title": "Publication" | | "title": "Publication" |
| } | | } |
| ], | | ], |
| "id": "f187e0ff-516d-455c-941e-bcf16891f7ed", | | "id": "f187e0ff-516d-455c-941e-bcf16891f7ed", |
| "isopen": false, | | "isopen": false, |
| "license_id": "notspecified", | | "license_id": "notspecified", |
| "license_title": "License not specified", | | "license_title": "License not specified", |
| "maintainer": null, | | "maintainer": null, |
| "maintainer_email": null, | | "maintainer_email": null, |
| "metadata_created": "2021-09-16T08:12:03.765285", | | "metadata_created": "2021-09-16T08:12:03.765285", |
n | "metadata_modified": "2022-04-27T18:10:38.333329", | n | "metadata_modified": "2022-04-27T18:11:37.663611", |
| "name": "malawi-integrated-hiv-program-report-2015-q3", | | "name": "malawi-integrated-hiv-program-report-2015-q3", |
| "notes": "A summary of the key achievements between July and | | "notes": "A summary of the key achievements between July and |
| September 2015 is provided below:\r\n\r\n* Scale-up of integrated HIV | | September 2015 is provided below:\r\n\r\n* Scale-up of integrated HIV |
| services had reached the following number of sites:\r\n * __724__ | | services had reached the following number of sites:\r\n * __724__ |
| static (579 within and 145 outside of health facilities) and 188 | | static (579 within and 145 outside of health facilities) and 188 |
| outreach HTC sites\r\n\r\n * __717__ (static) ART sites\r\n\r\n | | outreach HTC sites\r\n\r\n * __717__ (static) ART sites\r\n\r\n |
| * __619__ PMTCT sites (Option B+, all included in ART sites | | * __619__ PMTCT sites (Option B+, all included in ART sites |
n | above)\r\n\r\n * __663__ Pre-ART sites\r\n\r\n *__ 650__ sites | n | above)\r\n\r\n * __663__ Pre-ART sites\r\n\r\n * __ 650__ |
| with HIV-exposed child follow-up\r\n\r\n* __625,803__ persons were | | sites with HIV-exposed child follow-up\r\n\r\n* __625,803__ persons |
| tested for HIV and received their results; __190,051 (30%)__ accessed | | were tested for HIV and received their results; __190,051 (30%)__ |
| HTC for the\r\nfirst time; __435,752 (70%)__ were repeat testers and | | accessed HTC for the\r\nfirst time; __435,752 (70%)__ were repeat |
| __13,093 (3%)__ of these received confirmatory\r\ntesting (after | | testers and __13,093 (3%)__ of these received confirmatory\r\ntesting |
| having tested positive in the past). This is equivalent to 51% | | (after having tested positive in the past). This is equivalent to 51% |
| confirmatory testing\r\ncoverage among__ 25,737__ patients initiating | | confirmatory testing\r\ncoverage among__ 25,737__ patients initiating |
| ART this quarter. __34,966 (6%)__ clients received a | | ART this quarter. __34,966 (6%)__ clients received a |
| positive\r\nresult for the first time.\r\n\r\n* __16,645 (94%)__ of | | positive\r\nresult for the first time.\r\n\r\n* __16,645 (94%)__ of |
| __17,773 __blood units collected were screened for (at least) HIV, | | __17,773 __blood units collected were screened for (at least) HIV, |
t | hepatitis B and\r\nsyphilis.\r\n\r\n*__142,701 (91%)__ of __156,851__ | t | hepatitis B and\r\nsyphilis.\r\n\r\n* __142,701 (91%)__ of __156,851__ |
| women at ANC had their HIV status ascertained; __11,113 (8%)__ of | | women at ANC had their HIV status ascertained; __11,113 (8%)__ of |
| these\r\nwere HIV positive. __129,887 (97%)__ of __133,931__ women at | | these\r\nwere HIV positive. __129,887 (97%)__ of __133,931__ women at |
| maternity had their HIV status ascertained\r\n__9,868 (8%)__ of these | | maternity had their HIV status ascertained\r\n__9,868 (8%)__ of these |
| were HIV positive.\r\n\r\n* __ 25,737__ patients started ART this | | were HIV positive.\r\n\r\n* __ 25,737__ patients started ART this |
| quarter.\r\n\r\n* __585,660__ patients were alive and on ART by end of | | quarter.\r\n\r\n* __585,660__ patients were alive and on ART by end of |
| September 2015. This means that 59% of the\r\nestimated 1 million HIV | | September 2015. This means that 59% of the\r\nestimated 1 million HIV |
| positive population was on ART. 1 Estimated ART coverage among people | | positive population was on ART. 1 Estimated ART coverage among people |
| in\r\nneed for treatment1 was __50% (50,533 / 101,000)__ for children | | in\r\nneed for treatment1 was __50% (50,533 / 101,000)__ for children |
| (<15 years) and __68% (531,990 /\r\n779,000)__ for adults.\r\n\r\n* | | (<15 years) and __68% (531,990 /\r\n779,000)__ for adults.\r\n\r\n* |
| __78%__ of adults and __79%__ of children were retained alive on ART | | __78%__ of adults and __79%__ of children were retained alive on ART |
| at 12 months after initiation. Actual\r\nretention rates are thought | | at 12 months after initiation. Actual\r\nretention rates are thought |
| to be about 10% higher due to misclassification of \u2018silent | | to be about 10% higher due to misclassification of \u2018silent |
| transfers\u2019 as\r\ndefaulters in clinic-based survival/retention | | transfers\u2019 as\r\ndefaulters in clinic-based survival/retention |
| analysis. (see section 15.4)\r\n\r\n* __510,798 (93%)__ of __574,610__ | | analysis. (see section 15.4)\r\n\r\n* __510,798 (93%)__ of __574,610__ |
| patients on first line adult ART were on regimen 5A | | patients on first line adult ART were on regimen 5A |
| (TDF/3TC/EFV).\r\n\r\n* __11,823 2 (79%) __of an estimated __14,926__ | | (TDF/3TC/EFV).\r\n\r\n* __11,823 2 (79%) __of an estimated __14,926__ |
| HIV infected pregnant women in Malawi were on ART this\r\nquarter. | | HIV infected pregnant women in Malawi were on ART this\r\nquarter. |
| __7,031 (59%)__ of these were already on ART when getting pregnant and | | __7,031 (59%)__ of these were already on ART when getting pregnant and |
| __4,792 (41%)__ started\r\nART during pregnancy/delivery.\r\n\r\n* An | | __4,792 (41%)__ started\r\nART during pregnancy/delivery.\r\n\r\n* An |
| additional __1,555__ breastfeeding women started ART due to Option B+ | | additional __1,555__ breastfeeding women started ART due to Option B+ |
| (in WHO stage 1/2)\r\n\r\n* __78%, 71%, 67% and 66%__ of women started | | (in WHO stage 1/2)\r\n\r\n* __78%, 71%, 67% and 66%__ of women started |
| under Option B+ were retained on ART at 6, 12, 24 and\r\n36 months | | under Option B+ were retained on ART at 6, 12, 24 and\r\n36 months |
| after initiation, respectively.\r\n\r\n* __9,019 (7%)__ of infants | | after initiation, respectively.\r\n\r\n* __9,019 (7%)__ of infants |
| discharged alive from maternity were known to be HIV exposed, __8,414 | | discharged alive from maternity were known to be HIV exposed, __8,414 |
| (93%)__\r\nof these received ARV prophylaxis (nevirapine). __7,558 | | (93%)__\r\nof these received ARV prophylaxis (nevirapine). __7,558 |
| (84%)__ were enrolled in exposed child followup\r\nbefore age 2 | | (84%)__ were enrolled in exposed child followup\r\nbefore age 2 |
| months.\r\n\r\n* A total of __11,357__ HIV exposed children and | | months.\r\n\r\n* A total of __11,357__ HIV exposed children and |
| __6,929__ pre-ART patients were enrolled for follow-up in\r\nHIV Care | | __6,929__ pre-ART patients were enrolled for follow-up in\r\nHIV Care |
| Clinics (HCC) during this quarter.", | | Clinics (HCC) during this quarter.", |
| "num_resources": 1, | | "num_resources": 1, |
| "num_tags": 1, | | "num_tags": 1, |
| "organization": { | | "organization": { |
| "approval_status": "approved", | | "approval_status": "approved", |
| "created": "2021-10-14T11:02:35.234558", | | "created": "2021-10-14T11:02:35.234558", |
| "description": "The Department of HIV & AIDS (DHA) was established | | "description": "The Department of HIV & AIDS (DHA) was established |
| in 2001, initially as a unit in the Department of Clinical Services, | | in 2001, initially as a unit in the Department of Clinical Services, |
| to coordinate the biomedical HIV Program in Malawi. The department now | | to coordinate the biomedical HIV Program in Malawi. The department now |
| carries responsibility for various HIV related programs including: | | carries responsibility for various HIV related programs including: |
| sexually transmitted infections (STIs), prevention of mother to child | | sexually transmitted infections (STIs), prevention of mother to child |
| transmission of HIV (PMTCT), and national voluntary male medical | | transmission of HIV (PMTCT), and national voluntary male medical |
| circumcision program (VMMC). All these HIV program sub-sections are | | circumcision program (VMMC). All these HIV program sub-sections are |
| linked to one robust monitoring and evaluation sub-section in the HIV | | linked to one robust monitoring and evaluation sub-section in the HIV |
| and AIDS Department which technically operates under the Central | | and AIDS Department which technically operates under the Central |
| Monitoring and Evaluation Department (CMED) of the Ministry of | | Monitoring and Evaluation Department (CMED) of the Ministry of |
| Health.", | | Health.", |
| "id": "ca6a5fbb-31b1-44f8-9319-5da56d75a55b", | | "id": "ca6a5fbb-31b1-44f8-9319-5da56d75a55b", |
| "image_url": | | "image_url": |
| 2022-04-18-074318.527302WhatsApp-Image-2022-04-18-at-9.42.07-AM.jpeg", | | 2022-04-18-074318.527302WhatsApp-Image-2022-04-18-at-9.42.07-AM.jpeg", |
| "is_organization": true, | | "is_organization": true, |
| "name": "dha", | | "name": "dha", |
| "state": "active", | | "state": "active", |
| "title": "Department of HIV & AIDS and Viral Hepatitis", | | "title": "Department of HIV & AIDS and Viral Hepatitis", |
| "type": "organization" | | "type": "organization" |
| }, | | }, |
| "owner_org": "ca6a5fbb-31b1-44f8-9319-5da56d75a55b", | | "owner_org": "ca6a5fbb-31b1-44f8-9319-5da56d75a55b", |
| "private": false, | | "private": false, |
| "program_area": "Care and Treatment", | | "program_area": "Care and Treatment", |
| "relationships_as_object": [], | | "relationships_as_object": [], |
| "relationships_as_subject": [], | | "relationships_as_subject": [], |
| "resources": [ | | "resources": [ |
| { | | { |
| "cache_last_updated": null, | | "cache_last_updated": null, |
| "cache_url": null, | | "cache_url": null, |
| "created": "2022-03-23T19:56:39.801981", | | "created": "2022-03-23T19:56:39.801981", |
| "description": "", | | "description": "", |
| "format": "PDF", | | "format": "PDF", |
| "hash": "", | | "hash": "", |
| "id": "7a61aff4-2eda-417e-ab37-4b4466b30101", | | "id": "7a61aff4-2eda-417e-ab37-4b4466b30101", |
| "last_modified": "2022-04-04T23:37:43.975571", | | "last_modified": "2022-04-04T23:37:43.975571", |
| "lfs_prefix": | | "lfs_prefix": |
| "dha/malawi-integrated-hiv-program-report-2015-q3", | | "dha/malawi-integrated-hiv-program-report-2015-q3", |
| "metadata_modified": "2022-04-04T23:37:44.001835", | | "metadata_modified": "2022-04-04T23:37:44.001835", |
| "mimetype": "application/pdf", | | "mimetype": "application/pdf", |
| "mimetype_inner": null, | | "mimetype_inner": null, |
| "name": "malawi-integrated-hiv-program-report-2015-q3", | | "name": "malawi-integrated-hiv-program-report-2015-q3", |
| "package_id": "f187e0ff-516d-455c-941e-bcf16891f7ed", | | "package_id": "f187e0ff-516d-455c-941e-bcf16891f7ed", |
| "position": 0, | | "position": 0, |
| "resource_type": null, | | "resource_type": null, |
| "sha256": | | "sha256": |
| "5cc43f90cc9f2c43ed7f4e3f0f7e3890680685596aed78eee80fef792070eaf0", | | "5cc43f90cc9f2c43ed7f4e3f0f7e3890680685596aed78eee80fef792070eaf0", |
| "size": 2272881, | | "size": 2272881, |
| "state": "active", | | "state": "active", |
| "url": | | "url": |
| 4466b30101/download/malawi-integrated-hiv-program-report-2015-q3.pdf", | | 4466b30101/download/malawi-integrated-hiv-program-report-2015-q3.pdf", |
| "url_type": "upload" | | "url_type": "upload" |
| } | | } |
| ], | | ], |
| "state": "active", | | "state": "active", |
| "tags": [ | | "tags": [ |
| { | | { |
| "display_name": "Report", | | "display_name": "Report", |
| "id": "37e5a5df-a993-4d3f-8c9c-73c418c30f0f", | | "id": "37e5a5df-a993-4d3f-8c9c-73c418c30f0f", |
| "name": "Report", | | "name": "Report", |
| "state": "active", | | "state": "active", |
| "vocabulary_id": null | | "vocabulary_id": null |
| } | | } |
| ], | | ], |
| "title": "Malawi Integrated HIV Program Report 2015 Q3", | | "title": "Malawi Integrated HIV Program Report 2015 Q3", |
| "type": "dataset", | | "type": "dataset", |
| "url": null, | | "url": null, |
| "version": null, | | "version": null, |
| "year": "2015" | | "year": "2015" |
| } | | } |